All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
This is the H-2Db restricted epitope derived from the lymphocytic choreomeningitis virus (LCMV) glycoprotein gp 33; residues 33 to 41.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-L034 | Human anti-gp33 (KAVYNFATM) T Cell Receptor, pMSGV1 | LCMV | Human | KAVYNFATM | retroviral vector | |||
TCR-L035 | Human anti-gp33 (KAVYNFATM) T Cell Receptor, pMP71 | LCMV | Human | KAVYNFATM | retroviral vector | |||
TCR-L036 | Mouse anti-gp33 (KAVYNFATM) T Cell Receptor, pMP71 | LCMV | Mouse | KAVYNFATM | retroviral vector | |||
TCR-L034Z | Human anti-gp33 T cell receptor, pCDTCR1 | LCMV | Human | KAVYNFATM | Lentiviral | |||
TCR-L035Z | Human anti-gp33 (aa1-9) T cell receptor, pCDTCR1 | LCMV | Human | KAVYNFATM | Lentiviral | |||
TCR-L036Z | Mouse anti-gp33 (aa1-9) T cell receptor, pCDTCR1 | LCMV | Mouse | KAVYNFATM | Lentiviral | |||
TCR-C084Z | Mouse anti-gp33 (KAVYNFATC) T cell receptor (P14), pCDTCR1 | LCMV | P14 | Mouse | KAVYNFATC | H-2Db | Lentiviral | |
TCR-C085Z | Mouse anti-gp33 (KAVYNFATM) T cell receptor (P14), pCDTCR1 | LCMV | P14 | Mouse | KAVYNFATM | H-2Db | Lentiviral | |
TCR-L259 | Mouse anti-gp33 T cell receptor (P14), pCDTCR1 | LCMV | P14 | Mouse | EQKLISEEDL | HLA-A2 | Lentiviral | |
TCR-YC0510 | Mouse anti-gp33 T cell receptor ((P14)-1), pCDTCR1 | P14 | Mouse | KAVANFATM | H2-Db | Lentiviral vector | ||
TCR-YC0511 | Mouse anti-gp33 T cell receptor ((P14)-2), pCDTCR1 | P14 | Mouse | KAVFNFATM | H2-Db | Lentiviral vector | ||
TCR-YC0512 | Mouse anti-gp33 T cell receptor ((P14)-3), pCDTCR1 | P14 | Mouse | KAVSNFATM | H2-Db | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION